Nanomedicine for the management of lung and blood diseases

Nanomedicine

Volumn 4, Issue 3, 2009, Pages 331-339

  Buxton, Denis B ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Drug delivery; Gene therapy; Hematopoietic; Nanoparticle; Pulmonary; Thrombosis

Indexed keywords

ALBUMIN; AMIKACIN; ANTINEOPLASTIC AGENT; ARIKACE; CHITOSAN; CIPROFLOXACIN; CREMOPHOR; DOXORUBICIN; ECONAZOLE; GEMCITABINE; ISONIAZID; ITRACONAZOLE; LIPOSOME; MOXIFLOXACIN; NANOPARTICLE; PACLITAXEL; PLASMID VECTOR; POLOXAMER; POLYETHERURETHAN; POLYGLACTIN; PYRAZINAMIDE; RIFAMPICIN; SMALL INTERFERING RNA; SQUALENE; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

BLOOD CLOT LYSIS; BLOOD DISEASE; BRONCHIECTASIS; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; GENE THERAPY; HEART VALVE PROSTHESIS; HUMAN; LEUKEMIA; LOW DRUG DOSE; LUNG ASPERGILLOSIS; LUNG CANCER; LUNG DISEASE; LUNG INFECTION; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; LUNG TUBERCULOSIS; MATERIAL COATING; NANOENCAPSULATION; NANOMEDICINE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN PURIFICATION; RESPIRATORY TRACT INFECTION; REVIEW; SEPSIS; SINGLE DRUG DOSE; SOLID TUMOR; SUSTAINED RELEASE PREPARATION; THROMBOSIS; ANIMAL; HEMATOLOGIC DISEASE; METHODOLOGY; TISSUE ENGINEERING;

ANIMALS; DRUG DELIVERY SYSTEMS; HEMATOLOGIC DISEASES; HUMANS; LUNG DISEASES; NANOMEDICINE; NANOPARTICLES; TISSUE ENGINEERING;

EID: 66149123060     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.09.8     Document Type: Review

References (50)

1. Tam JM, McConville JT, Williams RO 3rd, Johnston KP: Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. J. Pharm. Sci.97,4915-4933 (2008).
2. Rogueda PG, Traini D: The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects. Expert Opin. Drug Deliv.4,595-606 (2007).
3. Rogueda PG, Traini D: The nanoscale in pulmonary delivery. Part 2: formulation platforms. Expert Opin. Drug Deliv.4,607-620 (2007).
4. Sungx JC, Pulliam BL, Edwards DA: Nanoparticles for drug delivery to the lungs. Trends Biotechnol.25,563-570 (2007).
5. Yang W, Peters JI, Williams RO 3rd: Inhaled nanoparticles - a current review. Int. J. Pharm.356,239-247 (2008).
6. Smola M, Vandamme T, Sokolowski A: Nanocarriers as pulmonary drug delivery systems to treat and diagnose respiratory and non respiratory diseases. Int. J. Nanomed.3,1-19 (2008).
7. Heyder J, Gebhart J, Rudolf G, Schiller C, Stahlhofen W: Deposition of particles in the human respiratory tract in the size range 0.005-015 pm. J. Aerosol Sci. 17,811-825 (1986).
8. Arnold MM, Gorman EM, Schieber LJ, Munson EJ, Berkland C: NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J. Control. Release121,100-109 (2007).
9. Alvarez CA, Wiederhold NP, McConville JT et al.: Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J. Infect. 55,68-74 (2007).
10. Tagalakis AD, McAnulty RJ, Devaney J et al.: A receptor-targeted nanocomplex vector system optimized for respiratory gene transfer. Mol. Ther. 16,907-915 (2008).
11. Meers P, Neville M, Malinin V et al.: Biofilm. penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemother.61,859-868 (2008).
12. Tseng C-L, Wu SY-H, Wang W-H et al.: Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials29,3014-3022 (2008).
13. Gradishar WJ: Albumin-bound paclitaxel: a next-generation taxane. Expert Opin. Pharmacother.7,1041-1053 (2006).
14. Rizvi NA, Riely GJ, Azzoli CG et al.: Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage FV non-small-cell lung cancer. J. Clin. Oncol.26,639-643 (2008).
15. Johnson CM, Pandey R, Sharma S et al.: Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected. with Mycobacterium tuberculosis. Antimicrob. Agents Chemother.49,4335-4338 (2005).
16. Ahmad Z, Pandey R, Sharma S, Khuller GK: Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles. Int. J. Antimicrob. Agents31,142-146 (2008).
17. Nguyen A J, Steele TWJ, Merkel O, Reul R, Kissel T: Fast degrading polyesters as siRNA nano-carriers for pulmonary gene therapy. J. Control. Release 132,243-251 (2008).
18. Konxx, Zhang W, Lockey RF et al.: Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene. Genet. Vaccines Ther.5,4 (2007).
19. Griesenbach U, Ferrari S, Geddes DM, Alton EW: Gene therapy progress and prospects: cystic fibrosis. Gene Ther.9,1344-1350 (2002).
20. Li S-D, Chono S, Huang L: Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J. Control. Release 126,77-84 (2008).
21. Li S-D, Chono S, Huang L: Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol. Ther. 16,942-946 (2008).
22. Heidel JD, Yu Z, Liu JY et al.: Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl Acad. Sci. USA 104,5715-5721 (2007).
23. Dames P, Gleich B, Flemmer A et al.: Targeted delivery of magnetic aerosol droplets to the lung. Nat. Nanotechnol.2,495-499 (2007).
24. Sharma AK, Zhang L, Li S et al.: Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant. J. Control. Release 131,220-227 (2008).
25. Reddy LH, Dubernet C, Mouelhi SL et al.: A new nanomedicine of genicitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J. Control. Release 124,20-27 (2007).
26. Reddy LH, Marque PE, Dubernet C et al.: Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine. J. Pharmacol. Exp. Ther. 325,484-890 (2008).
27. Reddy LH, Ferreira H, Dubernet C et al.: Squalenoyl nanomedicine of genicitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms. Anticancer Drugs 19,999-1006 (2008).
28. Schwulst SJ, Muenzer JT, Peck-Palmer OM et al.: Bim siRNA decreases lymphocyte apoptosis and improves survival in sepsis. Shock30,127-134 (2008).
29. Kidane AG, Buffiesci G, Comejo P et al.: Current developments and future prospects for heart valve replacement therapy. J. Biomed. Mater. Res. B Appl. Biomater. 88,290-303 (2009).
30. Nielsen VG, Kirklin JK, Holman WL et al.: Mechanical circulatory device thrombosis: a new paradigm linking hypercoagulation and hypofibrinolysis. ASAIO J. 54,351-358 (2008).
31. Jackson MJ, Robinson GM, Ali N et al.: Surface engineering of artificial heart valve disks
32. using nanostructured thin films deposited by chemical vapour deposition and sol-gel methods. J. Med. Eng. Technol.30,323-329 (2006).
33. Mirensky TL, Breuer CK: The development of tissue-engineered grafts for reconstructive cardiothoracic surgical applications. Pediatr. Res.63,559-568 (2008).
34. Ferraz N, Carlsson J, Hong J, Ott MK: Influence of nanoporesize on platelet adhesion and activation. J. Mater. Sci. Mater. Med. 19,3115-3121 (2008).
35. Ferr N, Nilsson B, Hong J, Karlsson Ott M: Nanoporesize affects complement activation. J. Biomed. Mater. Res. A87,925-931 (2008).
36. Marshx JN, Senpan A, Hu G et al.: Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomed.2,533-543 (2007).
37. Chua KN, Chai C, Lee PC et al.: Surface-aminated electrospun nanofibers enhance adhesion and expansion of human umbilical cord blood hematopoietic stem/progenitor cells. Biomaterials27,6043-6051 (2006).
38. Chua KN, Chai C, Lee PC et al.: Functional nanofiber scaffolds with different spacers modulate adhesion and expansion of cryopreserved umbilical cord blood hematopoietic stem/progenitor cells. Exp. Hematol.35,771-781 (2007).
39. Nichols JE, Cortiella J: Engineering of a complex organ: progress toward development of a tissue-engineered lung. Proc. Am. Thorac. Soc.5,723-730 (2008).
40. Chtouroux S, Porte P, Nogre M et al.: A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates. Vox Sang.92,327-337 (2007).
41. Kim IS, Choi YW, Kang Y et al.: Improvement of virus safety of an antihemophilc factor IX by virus filtration process. J. Microbiol. Biotechnol. 18,1317-1325 (2008).
42. Terpstra FG, Parkkinen J, Tolo H et al.: Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product. Vox Sang.90,21-32 (2006).
43. Nel A, Xia T, Madler L, Li N: Toxic potential of materials at the nanolevel. Science311,622-627 (2006).
44. Card JW, Zeldin DC, Bonner JC, Nestmann ER: Pulmonary applications and toxicity of engineered nanoparticles. Am. J. Physiol. Lung Cell. Mol. Physiol.295,L400-L411 (2008).
45. Poland CA, Duffin R, Kinloch I et al.: Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat. Nanotechnol.3,423-428 (2008).
46. Radomski A, Jurasz P, Alonso-Escolano D et al.: Nanoparticle-induced platelet aggregation and vascular thrombosis. Br. J. Pharmacol.146,882-893 (2005).
47. Li N, Xia T, Nel AE: The role of oxidative stress in ambient particulate matter-induced lung diseases and its implications in the toxicity of engineered nanoparticles. Free Radic. Biol. Med.44,1689-1699 (2008).
48. Shaw SY, Westly EC, Pittet MJ et al.: Perturbational profiling of nanomaterial biologic activity. Proc. Nad Acad. Sci. USA 105,7387-7392 (2008).
49. Guo J, Su H, Zeng Y et al.: Reknitting the injured spinal cord by self-assembling peptide nanofiber scaffold. Nanomed.3,311-321 (2007).
50. Segers VF, Tokunou T, Higgins LJ et al.: Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 16,1683-1692 (2007).